Scarica l'app Stockscreener
5.35
2.29%
0.12
Dopo l'orario di chiusura:
5.32
-0.03
-0.56%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MNKD Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$5.23
Aprire:
$5.23
Volume 24 ore:
5.30M
Relative Volume:
1.22
Capitalizzazione di mercato:
$1.64B
Reddito:
$248.37M
Utile/perdita netta:
$11.74M
Rapporto P/E:
107.00
EPS:
0.05
Flusso di cassa netto:
$18.24M
1 W Prestazione:
+4.09%
1M Prestazione:
-0.37%
6M Prestazione:
+18.10%
1 anno Prestazione:
-20.51%
Intervallo 1D:
$5.22
$5.39
Intervallo di 1 settimana:
$4.79
$5.39
Portata 52W:
$3.3812
$7.63
Mannkind Corp Stock (MNKD) Company Profile
Nome
Mannkind Corp
Settore
Industria
Telefono
818-661-5000
Indirizzo
1 CASPER STREET, DANBURY, CA
Confronta MNKD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
5.35 | 1.56B | 248.37M | 11.74M | 18.24M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-10 | Iniziato | Leerink Partners | Outperform |
| 2025-07-16 | Ripresa | H.C. Wainwright | Buy |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-02-10 | Iniziato | Wedbush | Outperform |
| 2024-12-20 | Iniziato | Wells Fargo | Overweight |
| 2024-12-19 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-09-09 | Ripresa | Leerink Partners | Outperform |
| 2024-06-13 | Iniziato | Rodman & Renshaw | Buy |
| 2023-10-10 | Iniziato | Wedbush | Outperform |
| 2021-05-14 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-12-24 | Iniziato | Oppenheimer | Outperform |
| 2019-10-25 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-05-14 | Iniziato | BTIG Research | Buy |
| 2019-03-04 | Iniziato | SVB Leerink | Outperform |
| 2019-02-22 | Iniziato | SVB Leerink | Outperform |
| 2018-02-28 | Downgrade | Maxim Group | Hold → Sell |
| 2017-11-01 | Downgrade | Maxim Group | Buy → Hold |
| 2017-10-10 | Iniziato | H.C. Wainwright | Buy |
| 2017-10-06 | Reiterato | Maxim Group | Buy |
| 2017-08-11 | Iniziato | Maxim Group | Buy |
| 2016-05-10 | Reiterato | Piper Jaffray | Underweight |
| 2016-05-10 | Reiterato | RBC Capital Mkts | Underperform |
| 2016-01-06 | Reiterato | Piper Jaffray | Underweight |
| 2016-01-06 | Reiterato | RBC Capital Mkts | Underperform |
| 2015-11-04 | Downgrade | RBC Capital Mkts | Outperform → Underperform |
| 2015-09-09 | Downgrade | Piper Jaffray | Neutral → Underweight |
| 2015-08-03 | Reiterato | RBC Capital Mkts | Outperform |
| 2015-05-11 | Downgrade | JP Morgan | Neutral → Underweight |
| 2015-05-11 | Reiterato | MLV & Co | Hold |
| 2015-04-16 | Reiterato | RBC Capital Mkts | Outperform |
Mostra tutto
Mannkind Corp Borsa (MNKD) Ultime notizie
How MannKind Corporation stock responds to policy changesTrade Risk Summary & Community Shared Stock Ideas - newser.com
Is MannKind Corporation stock attractive for retirement portfolios2025 Retail Activity & High Accuracy Trade Signal Alerts - newser.com
FDA accepts application for MannKind inhaled insulin in kids - MassDevice
MannKind (MNKD) Seeks FDA Approval for Afrezza in Younger Patien - GuruFocus
Is MannKind Corporation stock poised for growth2025 Technical Overview & Stepwise Swing Trade Plans - newser.com
MannKind (MNKD) Advances Inhaled Insulin for Pediatric Diabetes - GuruFocus
FDA accepts MannKind’s application for inhaled insulin in children - Investing.com
MannKind Corporation Submits Supplemental Biologics License Application for Needle-Free Afrezza Inhalation Powder for Pediatric Diabetes Treatment - Quiver Quantitative
Real time scanner hits for MannKind Corporation explainedMarket Trend Review & Free Reliable Trade Execution Plans - newser.com
MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes - Yahoo Finance
HC Wainwright & Co. Reiterates Buy Rating for MNKD with $11 PT | - GuruFocus
MannKind Corp. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
MannKind (NASDAQ:MNKD) Given "Hold (C)" Rating at Weiss Ratings - MarketBeat
Using data models to predict MannKind Corporation stock movement2025 Market Sentiment & Consistent Income Trade Ideas - newser.com
MannKind completes acquisition of scPharmaceuticals in $296.5 million deal - Investing.com
November 28th Options Now Available For MannKind (MNKD) - Nasdaq
Risk adjusted return profile for MannKind Corporation analyzedWeekly Trade Analysis & Accurate Technical Buy Alerts - newser.com
Heatmap analysis for MannKind Corporation and competitorsJuly 2025 Spike Watch & Verified Swing Trading Watchlist - newser.com
How moving averages guide MannKind Corporation tradingWatch List & Weekly Momentum Picks - newser.com
MannKind (NASDAQ:MNKD) Upgraded at Zacks Research - MarketBeat
MannKind completes acquisition of scPharmaceuticals By Investing.com - Investing.com Canada
MannKind completes acquisition of scPharmaceuticals; SCPH to be delisted from Nasdaq - Investing.com
MannKind (MNKD) Completes Acquisition of scPharmaceuticals to Bo - GuruFocus
MannKind completes acquisition of scPharmaceuticals - Investing.com
MannKind Corporation Completes Acquisition of scPharmaceuticals Inc. to Enhance Revenue Growth and Expand Cardiometabolic Therapy Portfolio - Quiver Quantitative
MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care - Yahoo Finance
>$370M annualized run rate: MannKind completes scPharmaceuticals acquisition, adds FUROSCIX - Stock Titan
A Fresh Look at MannKind (MNKD) Valuation Following Leadership Change with New Chief Medical Officer - simplywall.st
Does MannKind (NASDAQ:MNKD) Deserve A Spot On Your Watchlist? - Yahoo Finance
Why MannKind Corporation (NNFN) stock is trending on social mediaEarnings Summary Report & Safe Capital Growth Stock Tips - newser.com
How Dr. Ajay Ahuja’s Appointment at MannKind (MNKD) Has Changed Its Investment Story - simplywall.st
Assessing MannKind’s Share Price After FDA Clears Pediatric Use for Afrezza in 2025 - simplywall.st
Key metrics from MannKind Corporation’s quarterly dataRate Cut & Community Trade Idea Sharing - newser.com
Published on: 2025-10-02 20:45:52 - newser.com
Wedbush Maintains a Buy on MannKind Corporation (MNKD) - MSN
Revolution Medicines hires Mirati, ALX vet Sandler - BioCentury
MannKind Gets A Price Bump As Pipeline Progresses - Finimize
Is MannKind Corporation (NNFN) stock undervalued historicallyMarket Activity Summary & Daily Entry Point Trade Alerts - newser.com
Is MannKind Corporation a good long term investmentSector ETF Performance & Take Advantage of Momentum Stocks - earlytimes.in
MannKind (MNKD) Appoints New Chief Medical Officer - GuruFocus
MNKD Appoints New Chief Medical Officer to Strengthen Leadership Team - GuruFocus
MannKind appoints Ajay Ahuja as chief medical officer - Investing.com
MannKind Corporation Appoints Dr. Ajay Ahuja as Chief Medical Officer - Quiver Quantitative
Former Global Medical Head at Allergan: Dr. Ajay Ahuja Joins MannKind as Chief Medical Officer - Stock Titan
Will MannKind Corporation (NNFN) stock see insider accumulationJuly 2025 Rallies & Stock Timing and Entry Methods - newser.com
Will a bounce in MannKind Corporation offer an exitEarnings Overview Summary & Community Verified Swing Trade Signals - newser.com
Non Tuberculous Mycobacterial Infections Market Dynamics - openPR.com
MannKind (NASDAQ:MNKD) Shares Down 5%Time to Sell? - MarketBeat
MannKind (NASDAQ:MNKD) Earns Buy Rating from HC Wainwright - MarketBeat
Should you hold or exit MannKind Corporation nowWeekly Stock Recap & Scalable Portfolio Growth Ideas - newser.com
Price action breakdown for MannKind CorporationQuarterly Profit Report & Free Technical Confirmation Trade Alerts - newser.com
Mannkind Corp Azioni (MNKD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):